---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-020509"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:43:49.517386+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abbott issues $20B multi-tranche notes; proceeds to fund Exact Sciences acquisition

## Summary
- Issued $20B in senior notes across 8 tranches: floating and fixed rates from 3.70% to 5.60%, maturities 2029-2066.
- Net proceeds will fund the Exact Sciences acquisition, repay Exact Sciences debt, and for general corporate purposes.
- Underwriters include Morgan Stanley, Barclays, BofA Securities, and J.P. Morgan Securities.
- Closing expected on March 9, 2026, subject to customary conditions.

## SEC filing metadata
- accession: 0001104659-26-020509
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000110465926020509/0001104659-26-020509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000110465926020509/tm264905d7_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-020509
- JSON: https://secwatch.observer/filing/0001104659-26-020509.json
- Plain text: https://secwatch.observer/filing/0001104659-26-020509.txt

## Key facts
- Material Agreements
  ABBOTT LABORATORIES entered into Pricing Agreement with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC valued at $20,000,000,000 aggregate principal amount (effective 2026-02-23).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC
  - Value: $20,000,000,000 aggregate principal amount
  - Effective: 2026-02-23
  source text: On February 23, 2026, Abbott Laboratories (“Abbott”) entered into a pricing agreement (the “Pricing Agreement”), dated February 23, 2026, by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein (the “Underwriters”), pursuant to which Abbott agreed to issue and sell $20,000,000,000 aggregate principal amount of senior notes
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800/000110465926020509/0001104659-26-020509-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.